Save
New approaches at the horizon for 2L+ treatment of r/m CC
ESGO eAcademy, Faculty / Presenters, 373738
Current developments in 2L treatment of r/m CC
ESGO eAcademy, Faculty / Presenters, 373739
Recent and possible future changes in 1L treatment of r/r CC
ESGO eAcademy, Faculty / Presenters, 373736
Synthesizing the Data: Moving forward!
ESGO eAcademy, David Cibula, 373733
MIS in Early Cervical Cancer: No longer a standard
ESGO eAcademy, Pedro Ramirez, 373735
MIS in Early Cervical Cancer: Still Oncologically Safe
ESGO eAcademy, Henrik Falconer, 373734
Coloanal anastomosis after exenteration for recurrent cervical cancer
ESGO eAcademy, Luis Chiva, 373730
Vulvar and clitoral reconstruction using bilateral Singapore island perforator flap after anterior vulvectomy
ESGO eAcademy, Martina Angeles, 373728
Recurrent Cervical Cancer Case With Sacral Metastasis
ESGO eAcademy, Emin Erhan Donmez, 373732
Minimally invasive inguinal lymph node dissection technique
ESGO eAcademy, Hisham Abdel Mageed, 373731
Total Excision of Infrarenal Vena Cava in a Patient with Recurrent Endometrial Cancer
ESGO eAcademy, Emin Erhan Donmez, 373729
Surgery in relapsed ovarian cancer: whom, who, when, and how
ESGO eAcademy, Florian Heitz, 373727
Overview of the new quality indicators for cervical cancer management
ESGO eAcademy, Christina Fotopoulou, 373724
What is a high quality external beam radiotherapy for cervical cancer?
ESGO eAcademy, Cyrus Chargari, 373723
Rechallenge of bevacizumab: current evidence and potential clinical opportunities
ESGO eAcademy, Jean-Emmanuel Kurtz, 373726
PARP after PARP: what have we learned from the OREO/ENGOT-OV38 study
ESGO eAcademy, Antonio Gonzalez Martin, 373725
Quality indicators for uterovaginal brachytherapy
ESGO eAcademy, Remi Nout, 373722
Total resection of aggressive pelvic angiomyxoma by combination of robotic & vaginal approach.
ESGO eAcademy, Sergi Fernandez, 373719
Pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with Niraparib
ESGO eAcademy, Serena Maria Boccia, 373703
The significance of lower uterine segment involvement in endometrial cancer
ESGO eAcademy, Sharon Davidesko, 373707
The role of molecular classification in endometrial cancers with lymph nodes metastasis.
ESGO eAcademy, Gabriella Schivardi, 373712
The MULTISENT study: Analysis of survival according to the volume of sentinel lymph node disease
ESGO eAcademy, Silvia Cabrera Diaz, 373704
Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment
ESGO eAcademy, Giulio Bonaldo, 373709
BACK TO THE FUTURE: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification
ESGO eAcademy, Emanuele Perrone, 373711
Intermediate-risk endometrial cancer: isolated tumor cells (ITC) versus node-negative in sentinel lymph node mapping. An international multi-institutional comparative study
ESGO eAcademy, Giuseppe Cucinella, 373714
A predictive model for detection of epithelial ovarian cancer based on methylation landscape
ESGO eAcademy, Douglas VNP Oliveira, 373715
Laparoscopic cytoreducion for relapsed gynaecological cancer
ESGO eAcademy, Ignacio Zapardiel, 373718
Identifying women with early-stage cervical cancer at low risk of lymph node metastases, in a large international cohort - A logistic regression analysis, without sharing privacy-sensitive patient data
ESGO eAcademy, Hans Wenzel, 373713
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ)
ESGO eAcademy, Radoslav Chekerov, 373716
Agressive angiomyxoma of the pelvis and vagina: a robotic and vaginal combined approach
ESGO eAcademy, Ana Luzarraga, 373717
The case of laparoscopic anterior rectal resection and retransplantaion of theureter with the use of ICG.
ESGO eAcademy, Ewa Milnerowicz-Nabzdyk, 373720
Rectovaginal fistula repair by Martius flap after exclusive chemo-radiation in advanced cervical cancer patient. A case report
ESGO eAcademy, Vito andrea Capozzi, 373721
Symptomatic or asymptomatic recurrence of ovarian cancer: Does it influence survival?
ESGO eAcademy, Karen Madland, 373708
Comparison of PD-L1 status between primary and paired recurrent/metastatic cervical cancer
ESGO eAcademy, Beyhan Ataseven, 374704
Medical options in different ovarian cancer populations
ESGO eAcademy, Jonathan Ledermann, 373701
Pathology and molecular biology
ESGO eAcademy, Xavier Matias-Guiu, 373700
BRCA mutated ovarian cancer: PARP inhibitors, bevacizumab- how to choose maintenance therapy in practice
ESGO eAcademy, Susana Banerjee, 373697
Surgical aspects for early, advanced stage and recurrent disease
ESGO eAcademy, Anna Fagotti, 373702
HRD-positive ovarian cancer: PARP inhibitors, bevacizumab - how to choose maintenance therapy in practice
ESGO eAcademy, Isabelle Ray-Coquard, 373699
HRD-negative ovarian cancer: how to choose maintenance therapy in practice and future options
ESGO eAcademy, Antonio Gonzalez Martin, 373698
New Era of Immune Checkpoint Inhibitors in Endometrial Cancer: Q&A
ESGO eAcademy, Faculty / Presenters, 374425
The Future of ICI – PD-1/L1 Inhibitors in First-line Treatment of Endometrial Cancer
ESGO eAcademy, Mansoor Raza Mirza, 374424
Diagnosis and Treatment of Advanced EC: Patient Case Study
ESGO eAcademy, Christian Marth, 374423
Treatment of Recurrent EC with ICI: Patient Case Study
ESGO eAcademy, Lucy Gilbert, 374422
Where do Immune Checkpoint Inhibitors Fit in the Patient Journey?
ESGO eAcademy, Jalid Sehouli, 374421
The development of immunotherapy in gestational trophoblastic tumours
ESGO eAcademy, Benoit You, 373696
Management of Gestational Trophoblastic Tumours: Discussion about an illustrative patient case
ESGO eAcademy, Christian Marth, 373695
Role of chemotherapy and identification of new biological targets for drug development in gestational trophoblastic disease
ESGO eAcademy, Gloria Marquina, 373694
Discussant
ESGO eAcademy, Toon Van Gorp, 373688
Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: a prospective, open-label, randomized controlled phase
ESGO eAcademy, Zhiying Xu, 373687
Pembrolizumab Monotherapy for Advanced Clear Cell Gynaecological Cancer: Phase II PEACOCC Trial
ESGO eAcademy, Rowan Miller, 373691
Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer
ESGO eAcademy, Nanda Horeweg, 373690
The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
ESGO eAcademy, Domenica Lorusso, 373689
ESGO Presidential talk on ESGO 2022
ESGO eAcademy, Nicole Concin, 373684
Decoding Chaos - analysing the genome of ovarian high grade serous carcinoma
ESGO eAcademy, Iain Mcneish, 373683
Helga Salvesen Award for Best Translational Research: Introduction and announcement of the award
ESGO eAcademy, Mansoor Raza Mirza, 373686
ENGOT, ENYGO & ENGAGe Anniversary talk
ESGO eAcademy, Mansoor Raza Mirza, 373685
Introduction and announcement of competition
ESGO eAcademy, Anna Fagotti, 373682
Advances in endometrial & cervical cancers (ENGOT-EN6, KN775, KN826, EMPOWER, ENGOT-CX6)
ESGO eAcademy, Nicoletta Colombo, 373678
Major achievements in the management of ovarian cancer (SOLO1, PAOLA1, PRIMA, ATHENAmono, Atalante)
ESGO eAcademy, Mansoor Raza Mirza, 373679
Pro laparoscopic surgery, a conventional method with innovative possibilities
ESGO eAcademy, Mustafa Zelal Muallem, 373680
Pro robotics surgery, new options and indications
ESGO eAcademy, Henrik Falconer, 373681
Histopathology and staging of the disease
ESGO eAcademy, Alexandros Rodolakis, 373677
New ESGO-ESHRE-ESGE Guidelines on Fertility Sparing in Endometrial Cancer: Medical treatment
ESGO eAcademy, Giovanni Scambia, 373675
Oral posters session 2 : ID 648 - 999 - 922
ESGO eAcademy, Faculty / Presenters, 373668
Oral posters session 2 : ID 604 - 745 - 641
ESGO eAcademy, Faculty / Presenters, 373665
Oral posters session 2 : ID 781 - 1569 - 568
ESGO eAcademy, Faculty / Presenters, 373662
Clinical relevance of clinicopathological and molecular factors in women with surgically treated stage IV endometrial cancer
ESGO eAcademy, Linda Nooij, 373663
Fertility related issues, pregnancy, and ART
ESGO eAcademy, Kirsten Tryde Macklon, 373676
Session 4 | Burnout
ESGO eAcademy, Faculty / Presenters, 374599
Session 3 | Communicative skills training
ESGO eAcademy, Faculty / Presenters, 374598
Welcome speech on ESGO 2022
ESGO eAcademy, Faculty / Presenters, 373661
How to manage the side effects of single-agent immune checkpoint inhibitors
ESGO eAcademy, Ana Oaknin, 373658
Managing the challenge of combination therapies with immune checkpoint inhibitors: 2. Anti-angiogenic therapy
ESGO eAcademy, Jonathan Ledermann, 373657
All patients should have molecular testing - Pro
ESGO eAcademy, Domenica Lorusso, 373655
All patients should have molecular testing - Con
ESGO eAcademy, Glenn McCluggage, 373654
Managing the challenge of combination therapies with immune checkpoint inhibitors: 1. Chemotherapy
ESGO eAcademy, Nicoletta Colombo, 373659
Molecular classification for management of endometrial cancer: Discussion
ESGO eAcademy, Christian Marth, 373656
Surgery of the vulva and plastic reconstruction
ESGO eAcademy, Sven Mahner, 373653
Low anterior resection for advanced ovarian carcinoma, technical considerations to minimize postoperative complications
ESGO eAcademy, Ane Gerda Eriksson, 373648
Transvaginal single port laparoscopic for left ovarian cyst removal and bilateral tubal anastomosis
ESGO eAcademy, Ling Min, 373646
Surgery of the lymph nodes - groin and pelvis
ESGO eAcademy, Linn Woelber, 373652
Surgery for recurrence with pelvic exenteration
ESGO eAcademy, Nadeem R. Abu-Rustum, 373651
New Keystone flap application in vulvo-perineal reconstructive surgery for vulvar cancer.
ESGO eAcademy, Alfonso Altieri, 373650
Protected Laparoscopic Large Ovarian Cyst Aspiration - A five steps alternative to laparotomy
ESGO eAcademy, Houssein El Hajj, 373647
Impact of vaginal morbidity on sexual health in cervical cancer—insights from the EMBRACE study
ESGO eAcademy, Kathrin Kirchheiner, 373645
Pathology update
ESGO eAcademy, Maria Rosaria Raspollini, 373642
Systemic treatment in advanced and metastatic disease
ESGO eAcademy, Remi Nout, 373640
Impact of dilation and sexual activity on vaginal morbidity—preliminary results
ESGO eAcademy, Remi Nout, 373644
ENYGO-ENGAGe survey on sexual health after gynaecological cancer—preliminary results
ESGO eAcademy, Zoia Razumova, 373643
Definitive chemoradiation and brachytherapy
ESGO eAcademy, Jacob Lindegaard, 373641
Surgical treatment (T1a, T1b1-T1b3, FST, Cancer in pregnancy, Cancer from specimen after hysterectomy)
ESGO eAcademy, David Cibula, 373639
The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial
ESGO eAcademy, Yann Christinat, 373638
Overall Survival Results From ARIEL3: A Phase 3 Randomised, Double-blind Study of Rucaparib Vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma
ESGO eAcademy, Robert L Coleman, 373632
Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term secondary lifestyle behavioural outcomes
ESGO eAcademy, Michail Sideris, 373634
Discussant
ESGO eAcademy, Iain Mcneish, 373633
Validation Study of the “NOGGO-GIS ASSAY” based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial
ESGO eAcademy, Lukas C. Heukamp, 373636
Needs and barriers to providing sufficient gynaecological cancer care during the war in Ukraine - ENYGO survey results
ESGO eAcademy, Joanna Kacperczyk-Bartnik, 374727
Speech of the President of the Ukrainian Association of Gynecological Oncologists and Video report from Ukraine
ESGO eAcademy, Valentyn Svintsitskyi, 374726
Meet the Surgeon: How to manage vascular injury in the abdomen
ESGO eAcademy, Faculty / Presenters, 368190

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings